Effects of Exercise and GLP-1 Agonism on Muscle Microvascular Perfusion and Insulin Action in Adults With Metabolic Syndrome

NCT04575844 on ClinicalTrials.gov · last registry update 2026-05-06

Recruiting now, toward 80 participants. Due to report 30 April 2027, alongside 42 other tracked readouts that quarter. Primary outcome, as filed: Microvascular Blood Volume - change from baseline. Sponsors move these dates routinely; any movement since this site started watching is listed below. It has been running since 1 November 2020 — 5 years so far. liraglutide is approved in the US, but not for metabolic syndrome — a registration here is not an approval, and most drugs tested in a new condition never get one for it.

Status: RECRUITING
Phase: P4
Drug: liraglutide
Saxenda, Victoza, Xultophy
Sponsor: University of Virginia
Sponsor type: Other
Enrollment: 80
Started: 2020-11-01
Primary completion: 2027-04-30 estimated

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Microvascular Blood Volume - change from baseline

Conditions studied

Metabolic Syndrome

Every field above is taken directly from the registry record. See all detected changes across the class, or the liraglutide page for this molecule’s full trial and approval history.